Indoline derivatives functions as an inhibitors of
epidermal growth factor receptor (EGFR) with the anticancer potential against various
cancers. We aim to investigate anti-
breast cancer effects and mechanism of action of novel
indoline derivatives. Molecular docking of seven
indoline derivates with EGFR revealed,
N-(2-hydroxy-5-nitrophenyl (4'-methylphenyl) methyl) indoline (HNPMI) as the top lead compound. RT-PCR analysis showed the downregulation of PI3K/S6K1 genes in
breast cancer cells through the activation of EGFR with HNPMI. This compound found to have higher cytotoxicity than
Cyclophosphamide, with the IC50 of 64.10 μM in MCF-7 and 119.99 μM in SkBr3 cells. HNPMI significantly reduced the cell proliferation of MCF-7 and SkBr3 cells, without affecting non-cancerous cells, H9C2. Induction of apoptosis was analyzed by
Caspase-3 and -9, DNA fragmentation, AO/EtBr staining and flow cytometry assays. A fold change of 0.218- and 0.098- for
caspase-3 and 0.478- and 0.269- for
caspase-9 in MCF7 and SkBr3 cells was observed, respectively.
Caspase mediated apoptosis caused DNA fragmentation in
breast cancer cells upon HNPMI treatment. The structural elucidation of HNPMI by QSAR model and ADME-Tox suggests, a bi-molecular interaction of HNPMI-EGFR which is related to antiproliferative and apoptotic activity. The data concludes that, HNPMI-induced the apoptosis via EGFR signaling pathway in
breast cancer cells. Thus, HNPMI might serve as a scaffold for developing a potential anti-
breast cancer therapeutic agent.